Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer

Anirban Maitra shared on X:

“New in JAMA Oncology: Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer

Single institution trial from Yale. While the perioperative FOLFIRINOX question is mostly settled (trial ran from 2014 to 2021), the main take away points are the ctDNA and CK17 correlatives (see figures below).

The ctDNA data are particularly impressive and phenocopies what is seen with other GI cancers. This data again reinforces that even RESECTABLE pancreas cancer (borderline resectable) might benefit from neoadjuvant therapy to control micro metastatic disease.”

Source: Anirban Maitra/X

Dr. Anriban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.